Evidence map›Paper›PMID 30563284›Full record

ArticleMarine drugs2018

Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway.

Hung-Yun Lin, Shu-Leei Tey, Yih Ho, Yung-Tang Chin, Kuan Wang, Jacqueline Whang-Peng, Ya-Jung Shih, Yi-Ru Chen, Yung-Ning Yang, Yu-Cheng Chen and 3 more

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Molecular Targets and Signaling Pathways in Cholangiocarcinoma: A Systematic Review.Asian Pacific journal of cancer prevention : APJCP · 2023
    Pooled it
  2. Review
  3. Article
  4. The power of heteronemin in cancers.Journal of biomedical science · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Hung-Yun LinGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. linhy@tmu.edu.tw.
Shu-Leei TeyDepartment of Pediatrics, E-DA Hospital, Kaohsiung 824, Taiwan. djsr2000@hotmail.com.
Yih HoSchool of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan. yiho@tmu.edu.tw.
Yung-Tang ChinTaipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan. yutangchin@gmail.com.
Kuan WangTaipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan. Wangk@tmu.edu.tw.
Jacqueline Whang-PengGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. jqwpeng@gmail.com.
Ya-Jung ShihTaipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan. yajungshih@yahoo.com.tw.
Yi-Ru ChenTaipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan. aquarlus9132@yahoo.com.tw.
Yung-Ning YangDepartment of Pediatrics, E-DA Hospital, Kaohsiung 824, Taiwan. ancaly@yahoo.com.tw.
Yu-Cheng ChenThe Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung 404, Taiwan. j520c1@gmail.com.
Yi-Chang LiuDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. ycliu@cc.kmu.edu.tw.
Heng-Yuan TangPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA. tang506@gmail.com.
Yu-Chen Sh YangJoint Biobank, Office of Human Research, Taipei Medical University, Taipei 11031, Taiwan. can_0131@tmu.edu.tw.
E-Da Hospital · TWTaipei Medical University · TWChina Medical University · TWKaohsiung Medical University · TWWan Fang Hospital · TWAlbany College of Pharmacy and Health Sciences · USTaipei Medical University Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST106-2320-B-038-005Taipei Medical University TMU105-AE1-B41
6 · The paper itself

Abstract

A marine sesterterpenoid-type natural product, heteronemin, retains anticancer effects. In the current study, we investigate the antitumor mechanism of heteronemin in cholangiocarcinoma cells and further explore its molecular targets. Initially, heteronemin exhibited potent cytotoxic effects against cholangiocarcinoma HuccT1 and SSP-25 cells. In vitro, heteronemin altered the abilities of cell adhesion and cell migration in HuccT1 and SSP-25 cell lines. It repressed messenger ribonucleic acid (mRNA) expression levels of transforming growth factor (TGF)-β, mothers against decapentaplegic homolog (SMAD) and Myc, whose protein products play important roles in regulating cell growth, angiogenesis, and metastasis. In addition, heteronemin altered several signaling pathways. The results indicate that heteronemin was able to modulate cell adhesion, the expression of extracellular matrix (ECM) receptors, the TGF-β pathway, cell motility, the membrane integration, metastasis response, matrix metalloproteinase (MMP) remodeling, the regulation of metabolism, sprouting angiogenesis, transcription factors, and vasculogenesis in cholangiocarcinoma cell lines. The results also suggest that it activated multiple signal transduction pathways to induce an anti-proliferation effect and anti-metastasis in cholangiocarcinoma. In conclusion, heteronemin may be used as a potential medicine for anticancer therapy.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisBile Duct NeoplasmsCell Line, TumorCell MovementCell ProliferationCholangiocarcinomaDrug Screening Assays, AntitumorHumansPoriferaRNA, MessengerSignal TransductionTerpenesTransforming Growth Factor betaAntineoplastic Agents, PhytogenicheteroneminRNA, MessengerTerpenesTransforming Growth Factor betacholangiocarcinomaheteroneminTGF-β pathway

Identifiers

PMID30563284
PMCPMC6316595
OpenAlexW2904017238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.